Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients

Annals of Transplantation

Volumn 17, Issue 3, 2012, Pages 36-44

  Zochowska, Dorota ^a   Wyzgał, Janusz ^a   Paczek, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cyclosporine; Genetic polymorphism; Pharmacokinetics; Sirolimus

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; RAPAMYCIN; CYCLOSPORIN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; REAL TIME POLYMERASE CHAIN REACTION; ULTRAVIOLET SPECTROSCOPY; ALLELE; GENETICS; GRAFT REJECTION; INDIVIDUALITY; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALITY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SIROLIMUS;

EID: 84868701343     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.883456     Document Type: Article

References (23)

1. Min SI, Kim SY, Ahn SH et al: Cyp3A5*1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation, 2010; 90: 1394-400
2. Anglicheau D, Le Corre D, Lechaton S et al: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant patients on primary sirolimus therapy. Am J Transplant, 2005; 5: 595-603
3. von Ahsen N, Richter M, Grupp C et al: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem, 2001; 47: 1048-52
4. Op den Buijsch RA, Christiaans MH, Stolk LM et al: Tacrolimus pharmacokinetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol, 2007; 21: 427-35
5. van Schaik RH, de Wildt SN, van Iperen NM et al: Cyp3A4-V polymorphism detection by PCRrestriction fragment lenght polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem, 2000; 46: 1834-36
6. Rebbeck TR, Jaffe JM, Walker AH et al: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst, 1998; 90: 1225-29
7. Kadlubar FF, Berkowitz GS, Delongchamp RR et al: The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev, 2003; 12: 327-31
8. Tsuchiya N, Satoh S, Tada H et al: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 2004; 78: 1182-87
9. Anglicheau D, Thervet F, Etienne I et al: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther, 2004; 75: 422-33
10. Ping W, Xuefeng N, Mingli W et al: Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of Tacrolimus in Chinese renal transplant patients. Ann Transplant, 2011; 16: 54-60
11. Yates CR, Zhang W, Song P et al: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol, 2003; 43: 555-64
12. Le Meur Y, Djebli N, Szelag JC et al: CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther, 2006; 80: 51-60
13. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem, 2002; 48: 1668-71
14. Macphee IA, Fredericks S, Mohamed M et al: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation, 2005; 79: 499-502
15. Zheng H, Webber S, Zeevi A et al: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant, 2003; 3: 477-83
16. Fredericks S, Holt DW: Pharmacogenomics of immunosuppressive drug metabolism. Curr Opin Nephrol Hypertens, 2003; 12: 607-13
17. Amirimami B, Walker AH, Weber BL, Rebbeck TR: Response: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst, 1999; 91: 1588-90
18. Min DI, Ellingrod VL: Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit, 2003; 25: 305-9
19. Felix CA, Walker AH, Lange BJ et al: Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA, 1998; 95: 13176-81
20. Hesselink DA, van Schaik RH, van der Heiden IP et al: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003; 74: 245-54
21. Mourad M, Mourad G, Wallemacq P et al: Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation, 2005; 80: 977-84
22. Hu YF, Qiu W, Liu ZQ et al: Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol, 2006; 33: 1093-98
23. Haufroid V, Mourad M, van Kerckhove V et al: The effect of CYP3A5 and MDR1 (ABCB1) polymorphism on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 2004; 14: 147-54